AAAAAA

   
Results: 1-11 |
Results: 11
Allowable tension levels for overhead-line conductors
Authors: Barrett, JS Motlis, Y
Citation: Js. Barrett et Y. Motlis, Allowable tension levels for overhead-line conductors, IEE P-GEN T, 148(1), 2001, pp. 54-59
Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin inhealthy volunteers
Authors: Fossler, MJ Barrett, JS Hainer, JW Riddle, JG Ostegaard, P van der Elst, E Sprogel, P
Citation: Mj. Fossler et al., Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin inhealthy volunteers, AM J HEAL S, 58(17), 2001, pp. 1614-1621
Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis
Authors: Barrett, JS Gibiansky, E Hull, RD Planes, A Pentikis, H Hainer, JW Hua, TA Gastonguay, M
Citation: Js. Barrett et al., Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis, INT J CL PH, 39(10), 2001, pp. 431-446
Anticoagulant pharmacodynamics of tinzaparin following 175 IU/kg subcutaneous administration to healthy volunteers
Authors: Barrett, JS Hainer, JW Kornhauser, DM Gaskill, JL Hua, TA Sprogel, P Johansen, K van Lier, JJ Knebel, W Pieniaszek, HJ
Citation: Js. Barrett et al., Anticoagulant pharmacodynamics of tinzaparin following 175 IU/kg subcutaneous administration to healthy volunteers, THROMB RES, 101(4), 2001, pp. 243-254
Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 20th century
Authors: Hochhaus, G Barrett, JS Derendorf, H
Citation: G. Hochhaus et al., Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 20th century, J CLIN PHAR, 40(9), 2000, pp. 908-917
PhRMA perspective on population and individual bioequivalence
Authors: Barrett, JS Batra, V Chow, A Cook, J Gould, AL Heller, AH Lo, MW Patterson, SD Smith, BP Stritar, JA Vega, JM Zariffa, N
Citation: Js. Barrett et al., PhRMA perspective on population and individual bioequivalence, J CLIN PHAR, 40(6), 2000, pp. 561-570
Update to the PhRMA Perspective on Population and Individual Bioequivalence
Authors: Barrett, JS Batra, V Chow, A Cook, J Gould, AL Heller, AH Lo, MW Patterson, SD Smith, BP Stritar, JA Vega, JM Zariffa, N
Citation: Js. Barrett et al., Update to the PhRMA Perspective on Population and Individual Bioequivalence, J CLIN PHAR, 40(6), 2000, pp. 571-572
Limitations of the ruling span method for overhead line conductors at highoperating temperatures
Authors: Motlis, Y Barrett, JS Davidson, GA Douglass, DA Hall, PA Reding, JL Seppa, TO Thrash, F White, HB
Citation: Y. Motlis et al., Limitations of the ruling span method for overhead line conductors at highoperating temperatures, IEEE POW D, 14(2), 1999, pp. 549-560
Increasing thermal rating by risk analysis - Discussion
Authors: Barrett, JS Motlis, Y
Citation: Js. Barrett et Y. Motlis, Increasing thermal rating by risk analysis - Discussion, IEEE POW SY, 14(3), 1999, pp. 822-823
Disposition and exposure of the fibrinogen receptor antagonist XV459 on alpha(IIB)beta(3), binding sites in the guinea pig
Authors: Barrett, JS Yu, J Kapil, R Padovani, P Brown, F Ebling, WF Corjay, MH Reilly, TM Bozarth, JM Mousa, SA Pieniaszek, HJ
Citation: Js. Barrett et al., Disposition and exposure of the fibrinogen receptor antagonist XV459 on alpha(IIB)beta(3), binding sites in the guinea pig, BIOPHARM DR, 20(6), 1999, pp. 309-318
Moricizine bioavailability via simultaneous, dual, stable isotope administration: Bioequivalence implications
Authors: Pieniaszek, HJ Mayersohn, M Adams, MP Reinhart, RJ Barrett, JS
Citation: Hj. Pieniaszek et al., Moricizine bioavailability via simultaneous, dual, stable isotope administration: Bioequivalence implications, J CLIN PHAR, 39(8), 1999, pp. 817-825
Risultati: 1-11 |